Kalaris Therapeutics Accounts Payable

Kalaris Therapeutics (KLRS) currently reports a accounts payable of $910K as of March 2026. That compares with $2.4M in the prior-year period — down 61.9% year over year. Use the charts on this page to explore Kalaris Therapeutics's accounts payable history and peer comparisons.

Kalaris Therapeutics's accounts payable decreased from $2.4M to $910K — a 61.9% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kalaris Therapeutics reported $910K in accounts payable as of March 2026. That compares with $2.4M in the prior-year period — down 61.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $910K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Kalaris Therapeutics, and consider following KLRS for alerts when major investors trade the stock.

Kalaris Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $910K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KLRS with unrelated industries.